Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 264

1.

Estrogens and Coronary Artery Disease: New Clinical Perspectives.

Meyer MR, Barton M.

Adv Pharmacol. 2016;77:307-60. doi: 10.1016/bs.apha.2016.05.003. Epub 2016 Jun 29.

PMID:
27451102
2.

Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group.

N Engl J Med. 2016 Mar 31;374(13):1221-31. doi: 10.1056/NEJMoa1505241.

PMID:
27028912
3.

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.

Johnson KC, Aragaki AK, Jackson R, Reiner A, Sandset PM, Rosing J, Dahm AE, Rosendaal F, Manson JE, Martin LW, Liu S, Kuller LH, Cushman M, Rossouw JE.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):418-24. doi: 10.1161/ATVBAHA.115.306905. Epub 2015 Dec 17.

PMID:
26681757
4.

From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.

Valera MC, Gourdy P, Trémollières F, Arnal JF.

Maturitas. 2015 Nov;82(3):274-7. doi: 10.1016/j.maturitas.2015.07.012. Epub 2015 Jul 26. Review.

PMID:
26261036
5.

Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.

Prentice RL.

Semin Reprod Med. 2014 Nov;32(6):419-25. doi: 10.1055/s-0034-1384624. Epub 2014 Oct 16. Review.

6.

Body mass index, lipid metabolism and estrogens: their impact on coronary heart disease.

Kolovou GD, Kolovou V, Kostakou PM, Mavrogeni S.

Curr Med Chem. 2014;21(30):3455-65. Review.

PMID:
25174916
7.

Menopausal hormone therapy use in 17 European countries during the last decade.

Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S.

Maturitas. 2014 Nov;79(3):287-91. doi: 10.1016/j.maturitas.2014.07.002. Epub 2014 Aug 4. Erratum in: Maturitas. 2015 May;81(1):237-8.

PMID:
25156453
8.

Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.

Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN.

Ann Intern Med. 2014 Aug 19;161(4):249-60. doi: 10.7326/M14-0353.

PMID:
25069991
9.

What the future holds for women after menopause: where we have been, where we are, and where we want to go.

Lobo RA.

Climacteric. 2014 Dec;17 Suppl 2:12-7. doi: 10.3109/13697137.2014.944497. Epub 2014 Aug 27.

PMID:
25032478
10.

Risks and benefits of hormone therapy: has medical dogma now been overturned?

Shapiro S, de Villiers TJ, Pines A, Sturdee DW, Baber RJ, Panay N, Stevenson JC, Mueck AO, Burger HG.

Climacteric. 2014 Jun;17(3):215-22. doi: 10.3109/13697137.2014.905529. Epub 2014 Apr 23.

PMID:
24654673
11.

The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F.

J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009. Epub 2013 Oct 27. Review.

PMID:
24172877
12.

Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women.

Matsui S, Yasui T, Tani A, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Arisawa K, Irahara M.

Climacteric. 2014 Apr;17(2):191-6. doi: 10.3109/13697137.2013.856399. Epub 2013 Dec 16.

PMID:
24164272
13.

Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: a prospective study.

Cagnacci A, Zanin R, Napolitano A, Arangino S, Volpe A.

Contraception. 2013 Oct;88(4):539-43. doi: 10.1016/j.contraception.2013.04.003. Epub 2013 Apr 19.

PMID:
23683580
14.

Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.

Rossouw JE, Manson JE, Kaunitz AM, Anderson GL.

Obstet Gynecol. 2013 Jan;121(1):172-6. doi: http://10.1097/AOG.0b013e31827a08c8.

15.

The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes.

Alexander IM.

J Midwifery Womens Health. 2012 Nov-Dec;57(6):547-57. doi: 10.1111/j.1542-2011.2012.00247.x.

PMID:
23217066
16.

Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.

Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, Klein L, Manson JE, Martin LW, Robinson J, Wassertheil-Smoller S, Stefanick ML.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1108-16. doi: 10.1161/CIRCEP.112.972224. Epub 2012 Nov 20.

17.

Effects of estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women.

Allen AJ, McCubbin JA, Loveless JP, Helfer SG.

J Behav Med. 2014 Feb;37(1):94-101. doi: 10.1007/s10865-012-9468-3. Epub 2012 Nov 9.

PMID:
23135529
18.

Long term hormone therapy for perimenopausal and postmenopausal women.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004143. doi: 10.1002/14651858.CD004143.pub4. Review.

PMID:
22786488
19.

What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.

Simon JA.

Climacteric. 2012 Apr;15 Suppl 1:3-10. doi: 10.3109/13697137.2012.669332. Review.

PMID:
22432810
20.

Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.

Davey DA.

Womens Health (Lond). 2012 Mar;8(2):169-89. doi: 10.2217/whe.12.1. Review.

PMID:
22375720
Items per page

Supplemental Content

Loading ...
Write to the Help Desk